SEC Form 4 research
| Issuer | AN2 Therapeutics, Inc. |
|---|---|
| Tickers | ANTX |
| Reporting owners | 28 |
| Officers and directors | 10 |
| Last public filing | 2026-10-13 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-10-13 | 2026-10-12 | Marks Gilbert Lynn | A | 2,283 | $0 | Not reported |
| 2026-10-13 | 2026-10-12 | Martin Patricia A. | A | 389 | $0 | Not reported |
| 2026-10-13 | 2026-10-12 | Aziz Kabeer | A | 2,465 | $0 | Not reported |
| 2026-09-16 | 2026-09-15 | Trenor Cameron C. III | A | 116,667 | $0 | Not reported |
| 2026-09-16 | 2026-09-15 | Trenor Cameron C. III | A | 233,333 | $0 | Not reported |
| 2026-09-11 | 2026-09-09 | Readnour Robin Shane | S | 585 | $6.02 | Not reported |
| 2026-09-11 | 2026-09-09 | Readnour Robin Shane | S | 523 | $6.02 | Not reported |
| 2026-09-08 | 2026-09-08 | Readnour Robin Shane | S | 5,294 | $6.02 | Not reported |
| 2026-09-08 | 2026-09-08 | Readnour Robin Shane | S | 4,725 | $6.02 | Not reported |
| 2026-09-08 | 2026-09-03 | Readnour Robin Shane | S | 3,223 | $6.07 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.